The Desmoid Tumor Research Foundation

January 2014

Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors.

Author Information

Eiji Kozawa,Hiroshi Urakawa,Kunihiro Ikuta,Naohisa Futamura,Naoki Ishiguro,Shigeo Nakamura,Shunsuke Hamada,Yoshie Shimoyama,Yoshihiro Nishida

Department of Orthopedic Surgery, Nagoya University Graduate School and School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.

Publication

Summary

This study aimed to determine the prevalence of β-catenin nuclear positivity as a prognostic factor in patients with desmoid tumors (DTs) treated with meloxicam, a cyclooxygenase-2 (COX-2) selective inhibitor. Between 2003 and 2012, consecutive 31 patients with extraabdominal, sporadic DTs were prospectively treated with meloxicam as a systemic medical therapy. The nuclear expression of β-catenin can predict the efficacy of meloxicam treatment for patients with sporadic Dts.

View Abstract